The Best Reason To Buy AstraZeneca plc

Is there a truly convincing reason to buy AstraZeneca plc (LON: AZN)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

AstraZenecaThe FTSE’s second-biggest pharmaceuticals company AstraZeneca (LSE: AZN) (NYSE: AZN) has been in the news over the past year, with its share price having been boosted by the Pfizer bid attempt, to 4,573p today.

But are AstraZeneca shares worth buying? I say yes, and I’ll explain my key reason.

No undervaluation

Firstly, it’s not because of any obvious undervaluation. With a forward P/E of 17 for this year rising to 18 based on forecasts for 2015, I find AstraZeneca less favourably valued than GlaxoSmithKline right now — there’s a lower P/E and a higher dividend yield at Glaxo, with earnings growth expected sooner. But that’s all short term.

And to get the biggest elephant out of the way, I reject buying in the hope of a quick profit from any takeover. The price has already risen again, and it will no doubt spike even higher should there be a renewed bid. But it will almost as surely fall back again if Christmas and the New Year come and go and there’s no sign of Pfizer knocking at the door.

No, while a takeover windfall can be a nice bonus if we buy fundamentally sound shares, it’s not a long-term investing strategy — it’s really just a gamble.

What about cash?

Dividends? They’ve been held at 280 cents per share for the past three years, and with the share price having risen you’d be on for a forecast 3.8% yield at today’s price. That’s still pretty nice, but it’s not yet backed by rising earnings, and it is easily beaten by Glaxo’s mooted 5.7%.

Is my optimism based on the whirlwind known as Pascal Soriot, the new man at the helm since October 2012?

Now we’re getting there. AstraZeneca’s big problem was not simply the pain of the so-called patents cliff when it lost protection on some key drugs. No, it was the absence of any real clue what to do about it.

But Mr Soriot has provided that clue, and has done what with hindsight seems obvious — he’s refocused on AstraZeneca’s core strength of leading the market in major drug discovery and development. But that alone would not satisfy me, not without any results to show for it.

The pipeline!

And that brings me to the key piece of evidence, AstraZeneca’s rejuvenated development pipeline.

At the first-half stage this year, there were 14 projects in Phase III, up from 8 a year previously, moving Mr Soriot to say “We now have one of the most exciting pipelines in the industry“. That number has since risen to 15. And a lot of these candidates are in the critical, and potentially lucrative, field of oncology.

In a few years time I hope we’ll look back on these days as just a start, as major new drugs find their way to approval and widespread use — just as long as AstraZeneca’s shareholders are wise enough to keep Pfizer’s grubby paws off their treasure.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any shares mentioned. The Motley Fool UK has recommended shares in GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »

Investing Articles

Investing £5 a day could help me build a second income of £329 a month!

This Fool explains how £5 a day, or one less takeaway coffee, could help her build a monthly second income…

Read more »

Smart young brown businesswoman working from home on a laptop
Investing Articles

2 FTSE income stocks investors should consider buying in April

Income stocks are a great way to build wealth. Our writer details two picks she believes investors should consider snapping…

Read more »

Investing Articles

What might the 5-year price chart tell us about BT shares?

Christopher Ruane considers what clues the long-term performance of BT shares might offer him about business performance and whether to…

Read more »